Top Markets
Coin of the day
Sinew Pharma Inc. Sinew Pharma Inc.

Sinew Pharma Inc.

6634
Rang in Aktien #20226
Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research,... Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.
Aktienkurs
$1.91
Marktkapitalisierung
$136.47M
Veränderung (1 Tag)
-1.15%
Veränderung (1 Jahr)
21.17%
Land
TW
Handel Sinew Pharma Inc. (6634)

Kategorie

EPS für Sinew Pharma Inc. (6634)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Sinew Pharma Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Sinew Pharma Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
- -
CH
$-7.98 -
US